Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~ALL PARTICIPANTS:~* Body Mass Index (BMI) of 18 to 40 kg/m\^2; and a total body weight \>50 kg (110 lbs)~* Male or female not of reproductive potential~* If a female of reproductive potential, agrees to remain abstinent from heterosexual activity or agree to use or have their partner use 2 methods of acceptable contraception to prevent pregnancy while the participant is receiving study medication and for 14 days after the last dose of study medication PARTICIPANTS WITH NORMAL HEPATIC FUNCTION~* Healthy with normal hepatic function PARTICIPANTS WITH HEPATIC IMPAIRMENT~* Satisfy the criteria for Child-Pugh classification \[moderate (Part 1): Child-Pugh Scores 7-9 points, mild (Part 2): Child-Pugh Scores 5-6 points\] within 14 days before administration of study medication~* A diagnosis of hepatic impairment due to primary liver disease and not secondary to other diseases~* Stable hepatic impairment, defined as no clinically-significant change in disease status within the last 30 days~* On a stable dose of medication and/or treatment regimen used to manage hepatic disease for at least 4 weeks prior to study start~Exclusion Criteria:~ALL PARTICIPANTS~* A known hypersensitivity or intolerance to ertugliflozin or any other Sodium-Glucose co-Transporter 2 (SGLT2) inhibitor (i.e., canagliflozin \[Invokana\], dapagliflozin \[Farxiga\], empagliflozin, or ipragliflozin)~* Febrile illness within 5 days prior to the first dose of study medication~* Any clinically significant malabsorption condition~* A positive urine drug screen for drugs of abuse or recreational drugs~* Abuse of alcohol or binge drinking and/or any other illicit drug use or dependence within 6 months of study start~* Treatment with an investigational drug within 30 days preceding the first dose of study medication~* Pregnant or breastfeeding females~* Use of herbal supplements within 28 days prior to the first dose of study medication~* Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 56 days prior to dosing~* History of sensitivity to heparin or heparin-induced thrombocytopenia PARTICIPANTS WITH NORMAL HEPATIC FUNCTION~* Use of prescription drugs (hormonal methods of birth control are allowed), vitamins, and dietary supplements within 7 days prior to the first dose of study medication~* Positive serology for Hepatitis B or C PARTICIPANTS WITH HEPATIC IMPAIRMENT~* Hepatic carcinoma and hepatorenal syndrome or life expectancy less than 1 year~* Undergone portal-caval shunt surgery~* History of gastrointestinal hemorrhage due to esophageal varices or peptic ulcers less than 1 month prior to study entry~* Signs of significant hepatic encephalopathy~* Severe ascites and/or pleural effusion~* A transplanted kidney, heart or liver~* Received any of the following medications within 7 days prior to the first dose of study medication or during the study: other SGLT2 inhibitors (eg, dapagliflozin, canagliflozin, empagliflozin, and ipragliflozin); any potent drug-metabolizing enzyme-inducing drug, including rifampin, phenytoin, and carbamazepine; probenecid, valproic acid, gemfibrozil

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Ertugliflozin 15 mg - Moderate Hepatic Impairment (Type: EXPERIMENTAL): Participants receive a single 15 mg oral dose (tablet) of ertugliflozin
- Ertugliflozin 15 mg - Healthy Participants (Type: OTHER): Participants receive a single 15 mg oral dose (tablet) of ertugliflozin
- Ertugliflozin 15 mg - Mild Hepatic Impairment (Type: EXPERIMENTAL): Participants receive a single 15 mg oral dose (tablet) of ertugliflozin

Based on this trial design, predict the completion outcome and termination type (if applicable).